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Is Hospital Admission for
Heart Failure Really Necessary?
The Role of the Emergency Department and
Observation Unit in Preventing Hospitalization and Rehospitalization
Sean P. Collins, MD, MSC,* Peter S. Pang, MD,† Gregg C. Fonarow, MD,‡
Clyde W. Yancy, MD, MSC,† Robert O. Bonow, MD, MS,† Mihai Gheorghiade, MD†
Nashville, Tennessee; Chicago, Illinois; Los Angeles, California
Approximately 800,000 times a year, an emergency physician admits a patient with symptomatic heart failure (HF). Yet
only a minority of emergency department patients with HF are severely ill as a result of pulmonary edema, myocardial isch-
emia, or cardiogenic shock. The majority of patients are not in need of an acute intervention beyond decongestion, and few
patients during hospitalization undergo invasive diagnostic testing or therapeutic procedures that require intense monitor-
ing. Although hospitalization is clearly an inflection point, marking a threshold that independently predicts a worse outcome,
the exact impact of hospitalization on post-discharge events has not been well elucidated. Thus, large subsets of patients
with HF are hospitalized without a clear need for time-sensitive therapies or procedures. The authors estimate that up to
50% of emergency department patients with HF could be safely discharged after a brief period of observation, thus avoid-
ing unnecessary admissions and minimizing readmissions. Observation unit management may be beneficial for low-risk
and intermediate-risk patients with HF as continued treatment, and more precise risk stratification may ensue, avoid-
ing inpatient admission. Whether observation unit management is comparable with or superior to the current ap-
proach must be determined in a randomized clinical trial. Critical end points include time to symptom resolution and
discharge, post-discharge event rates, and a cost-effective analysis of each management strategy. It is the authors’
strong assertion that now is the time for such a trial and that the results will be critically important if we are to effec-
tively influence hospitalizations for HF in the near future. (J Am Coll Cardiol 2013;61:121–6) © 2013 by the
American College of Cardiology Foundation
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cian admits a patient with symptomatic heart failure (HF).
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ccepted August 30, 2012.with HF are severely ill as a result of pulmonary edema,
myocardial ischemia, or cardiogenic shock (1–3). Although
additional patients, such as those with advanced HF who
decompensate, genuinely require admission, a sizable pro-
portion of ED patients with HF present a disposition
challenge: “Can this ED patient with HF be safely dis-
charged to home?” When managing a severely ill patient
See page 127
with HF in the ED, the answer is easy: no. However, many
ED patients with HF are not acutely ill, have congestion
due to worsening chronic HF, and require only symptom-
atic treatment (4,5). In fact, patients are most often admit-
ted because of the uncertainty regarding post-discharge
events, which may be inversely related to their appearance
on initial presentation. We believe that a large number of
these admissions could be avoided, yet patients could still
receive timely and effective care.
ED presentations for HF have mirrored those of acute
coronary syndromes, but the success of the acute care
algorithms has not been the same. Both disease processes
122 Collins et al. JACC Vol. 61, No. 2, 2013
Is Hospitalization for HF Necessary? January 15, 2013:121–6have gone through an evolution
of therapies on the basis of a
better understanding of patho-
physiology and aimed at improv-
ing outcomes. Patients with
acute coronary syndromes are
now treated with aggressive
medical therapy in the ED, in-
cluding early definitive interventions, and at hospital dis-
charge, patients are treated with appropriate secondary
prevention measures aimed at minimizing acute coronary
syndrome recurrence and readmissions. Recently, there have
been similar advances in the outpatient management of HF.
Patients with systolic dysfunction now benefit from
angiotensin-converting enzyme inhibitors or aldosterone
receptor antagonists, beta-blockers, resynchronization ther-
apy, and implantable defibrillators (6). Outcomes have
improved largely because of these improvements in outpa-
tient therapy, but acute care pathways have not consistently
optimized the use of evidence-based, guideline-driven care.
Two critical unmet needs remain. Those patients with HF
and preserved systolic function have no therapy of proven
benefit. Furthermore, specific ED-based therapeutic inter-
ventions lack a solid evidence base. Regardless of ejection
fraction, patients with HF have a high rate of early post-
discharge events, with mortality and/or rehospitalization
affecting approximately 33% of patients within 60 to 90 days
(7). However, it is not clear that hospitalization per se is the
answer to decreasing these post-discharge event rates, while
it is reasonably clear that optimizing process-of-care strat-
egies is associated with better short-term and long-term
outcomes. As we continue to test new therapies to reduce
symptoms and improve outcomes in HF, and as we struggle
to reduce the enormous costs associated with hospitaliza-
tions for HF, it is desirable to evaluate alternatives to
hospitalization.
Although hospitalization is clearly an inflection point,
marking a threshold that independently predicts a worse
outcome, the exact impact of hospitalization on post-
discharge events has not been well elucidated (8,9). This is
especially the case because many HF hospitalizations are
driven by gaps in the process of care rather than worsening
pathophysiology. Further research is required to determine
if hospitalization is merely a marker of high risk, if treat-
ment or lack of treatment somehow affects post-discharge
outcomes, or if certain hospitalizations have no impact on
outcomes at all. Several registry findings suggest that for
some patients, hospitalization may not significantly affect
the high event rate. First, the majority of patients are not in
need of an acute intervention beyond decongestion. Al-
though most are still admitted to the hospital, in part
because of complex medical comorbidities, the treatment
received is solely intravenous diuretic agents (4,10–12).
Second, few patients during hospitalization undergo inva-
sive diagnostic testing or therapeutic procedures that require
Abbreviations
and Acronyms
ED  emergency
department
HF  heart failure
OU  observation unitintense monitoring (13). Third, patients who require intra-venous inotropic agents, mechanical circulatory support, or
hemodynamic monitoring account for a minority of admis-
sions (14,15). Thus, a large subset of patients with HF are
hospitalized without a clear need for time-sensitive thera-
pies or procedures.
Emergency Department
Disposition for Acute Heart Failure
Currently, about 10% to 20% of ED presentations for HF
are discharged directly home (10). Selecting the proper
patient for ED-based management is important, because
simply triaging a larger number of patients to discharge
from the ED is not the answer. Patients discharged directly
from the ED have higher post-discharge event rates than
the 20% to 30% encountered after discharge from an
inpatient setting (16,17). Improving initial risk stratification
to safely increase ED discharges, or transition low-risk
patients to alternative treatment pathways, thus avoiding
hospitalization, is crucial to conserving health care re-
sources, if this can be accomplished with similar clinical
outcomes as conventional strategies. Importantly, many
patients who return to the ED soon after discharge are also
admitted to the hospital, but approximately 40% of these
admissions are for noncardiac reasons (18,19). The majority
of these noncardiac readmissions also present for initial
evaluation to the ED. Regardless of etiology, reducing
preventable 30-day readmissions for patients discharged
after HF hospitalization is a national quality improvement
initiative, with financial consequences for hospitals that
have high rates of readmission.
We postulate that a 2-level targeted ED evaluation is
imperative to determine an ED patient’s risk profile and
discharge eligibility. The first level of risk stratification
explores 3 broad areas during the initial ED evaluation to
identify patients with high-risk features (11) (Table 1):
1) important precipitants, such as ischemia, uncontrolled
arrhythmias, and infection; 2) presenting hemodynamic
status, such as hypoxia, low blood pressure, and cardiogenic
shock; and 3) other confounding or contributing conditions,
such as renal dysfunction, hyponatremia, chronic obstructive
lung disease, and diabetes. Simple diagnostic testing and
physical examination can identify the vast majority of these
potential high-risk features. Thus, status at the time of
initial presentation will determine a large component of the
risk profile associated with early ED disposition decision
making.
Concurrent with the diagnostic workup, ED treatment is
also begun. This is largely in the form of intravenous
diuretic agents and topical or sublingual nitroglycerin.
Evaluation after initial treatment is an important second
level of ED risk stratification. Patients generally take 1 of 3
pathways after ED therapy, and depending on their re-
sponse, the remaining balance of risk can be determined.
The first group is composed of low-risk patients who
respond to initial therapy, returning quickly to their baseline
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eligible for ED discharge, in lieu of or after a brief period of
observation (20). The second group constitutes the high-
risk patients, representing about 20% of all ED patients, who
evelop a worsening clinical profile after therapy. This profile
ncludes continued symptoms, worsening renal function, hy-
otension, or an elevated troponin. These patients would be
oor candidates for ED discharge and should be promptly
riaged to an inpatient unit for early interventions and further
are (21). The third group consists of patients with interme-
iate risk, who have a partial response to therapy, in which
ymptoms diminish partially, with none of the high-risk
eatures developing. However, because of their incomplete
esponse, they require continued treatment and observation.
This ED-based, 2-level risk stratification provides a
oundation for disposition decision making. Those deemed
t high risk, either at initial evaluation or after initial
herapy, should be admitted to the hospital for more
omprehensive evaluation, treatment, and risk assessment.
owever, in those without high-risk features, we propose
n alternative to conventional hospitalization.
lternatives to Hospitalization in Patients
ot Eligible for Emergency Department Discharge
atients who are hospitalized for HF receive ongoing acute
herapy with the goal of optimizing volume status, leading
o symptom reduction and thus facilitating discharge. These
atients with HF are in need of an “inpatient equivalent,”
hereby acute therapy can be delivered, inexpensive testing
can be conducted, an effective care transition can be planned,
and inpatient hospitalization can be avoided. The importance
of this is highlighted by the fact that the National Heart, Lung,
and Blood Institute has identified effective alternatives to
hospital admission in ED patients with HF as a high priority
(22). We believe there is a sizable subset of ED patients with
HF who would benefit from a period of observation and
Initial Approach to ED Patients With HF Identifying Important Acutand Other Contributing Condi ionsTable 1 I itial Approach o ED Patients With HF Iden ifying Imand Other Contributing Conditions
Prognostic Factor Assessment
Acute precipitants
Ischemia ECG and troponin
Infection Chest radiography, physical exam, urinalysis
Arrhythmia ECG
Hemodynamic status
Hypotension Vital signs
Hypoxia Pulse oximetry
Organ perfusion Mental status, capillary refill
Contributing conditions
Renal dysfunction BUN, creatinine
Hyponatremia Serum sodium level
COPD Pulse oximetry
Diabetes Blood glucose
BUN  blood urea nitrogen; COPD  chronic obstructive pulmonary disease; ECG  electrocardiotreatment, thus avoiding inpatient admission.Investing in a new ED approach to patients with HF is
instrumental if we aim to reduce hospital admissions and
readmissions. Because more than 80% of HF admissions
and readmissions originate in the ED, emergency physicians
serve an important role as gatekeepers for inpatients with
HF. They are ideally positioned to facilitate a paradigm
shift away from hospital admission and toward observation
unit (OU) management. We estimate that up to 50% of
patients with HF could be safely discharged from the ED
after a brief period of observation, thus avoiding unnecessary
admissions and minimizing readmissions (23,24). This
would be a significant change to our current approach of
nearly universal hospitalization in ED patients with HF
who currently cannot be discharged directly from the ED.
Conservatively, changing the disposition decision from
admission to an OU stay in merely 5% of the 400,000
“non-high-risk” patients would result in savings of 80,000
hospital days and more than $80 million annually in the
United States (20,000 patients at an average cost savings of
$4,000 each) (25,26).
Importantly, the OU is an ideal place to address many of
the issues that hamper ED discharge and have been asso-
ciated with early readmission in patients with HF (Table 2).
OU management is compelling for HF management for
several other reasons. First, a high proportion of patients
experience improvement in dyspnea during their ED stays
as a result of standard therapy (27). Many have complete
resolution within 24 hours of initial therapy, which is the
typical time period of observation. Second, the monitoring
of blood pressure, heart rate, urine output, and body weight
can be readily provided in the OU. Third, the simple
diagnostic testing that occurs during an inpatient admission,
such as electrolyte testing, echocardiography, B-type natri-
uretic peptide or N-terminal pro–B-type natriuretic peptide,
and serial troponin measurements can easily be performed in
the OU. Fourth, HF education and arranging outpatient
cipitants, Hemodynamic Status,nt Acute Pr cipita ts, Hemodynamic Status,
ED Intervention
Antiplatelet agents, reperfusion, nitroglycerin
Antibiotic agents, occasionally intravenous fluids
Rate and rhythm control via pharmacotherapy or electrical cardioversion
Intravenous fluids, vasopressors, inotropes
Oxygen, NIV, intubation
Intravenous fluids, vasopressors, inotropes
Vasodilators, diuresis, intravenous fluids
Fluid restriction
Bronchodilators, steroids, oxygen
Insulin, oral hypoglycemic agents
; ED  emergency department; HF  heart failure; NIV noninvasive ventilation.e Preportafollow-up are key components of OU management. These 2
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incorporated in recently updated American College of
Cardiology and American Heart Association performance
measures, and are key components of OU management
(28–30). Nonetheless, OU management for HF continues
to be vastly underused.
The purpose of an OU is to simultaneously treat and
risk-stratify patients while determining the need for hospi-
talization. The typical entry point for OU admission is the
ED, where initial evaluation and treatment occur. Consen-
sus guidelines have been developed to identify appropriate
ED patients with HF for OU management (31) (Table 3).
Although patients found to be at high risk would be
ineligible for OU management, more than 50% of ED
patients qualify for OU management. After OU evaluation,
the 75% of patients who have responded to therapy, have no
identifiable high-risk features, and have satisfactory
follow-up care plans are discharged home. Their rates of
readmission are similar to or better than those who are
managed in an inpatient setting (32). Patients with inadequate
responses to initial therapy or with high-risk features identified
during their OU stays are admitted to the hospital for further
management. The OU has been used to safely discharge and
conserve resources in ED patients with HF (32).
The interventions in the OU are not complex or costly
and in fact conserve significant resources compared with
admission. If the OU is safe and efficient and minimizes
health care expenditures, why have OUs not been univer-
sally implemented? The need for skillful coordination of the
transition of care and the absence of a robust database to
demonstrate noninferiority, if not superiority, to conven-
Common Observation UnitIntervention Th May Facilitate Safeand Early Discharge and Avo d Inpatient Admission
Table 2
Common Observation Unit
Interventions That May Facilitate Safe
and Early Discharge and Avoid Inpatient Admission
Issue to Be Addressed Method
1. Observe response to
therapy
1. Vital signs, dyspnea testing, urine
output
2. Identify high-risk features 2. Serial troponin and ECG, electrolytes,
renal function
3. Routine diagnostic testing 3. Echocardiography
4. HF education 4. Educational pamphlets, videos, and
personalized teaching by nurse
practitioner
5. Guideline-directed
medical therapy for HF
a) ACEinhibitors/ARBs
b) Beta-blockers
c) Aldosterone antagonists
d) Oral loop diuretic agents
5. Prescriptions filled before discharge,
documented plan for dose titration
and provision of close monitoring
6. Arrange early follow-up 6. HF team member meets with patient
at time of discharge and arranges
follow-up in 7 days
7. Optimize medication
regimen
7. HF team member ensures proper
regimen individualizing to the
patient’s EF and comorbidities
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; ECG  electrocardi-
graphy; EF  ejection fraction; HF  heart failure.tional care remain significant hurdles. Previously, there werefew financial incentives for selecting an OU stay over
inpatient hospitalization for HF. However, that has
changed as the Centers for Medicare and Medicaid Services
provide reimbursement for OU-based HF care while insti-
tuting penalties for excessive hospital readmissions.
There are several necessary steps to maximize OU use and
optimize patient management: 1) at the local level, increased
collaboration among emergency physicians, cardiologists,
hospitalists, and primary care physicians to ensure continu-
ity of care from ED admission through hospital discharge
and outpatient follow-up; 2) at the national level, the dissem-
ination of successful protocols, including patient selection and
therapeutic pathways; and 3) from a research perspective,
patient selection, comparative outcome, and cost-effectiveness
studies further identifying optimal OU patients and protocols
that maximize health care resource utilization.
Future Directions
Evidence-based therapies have resulted in improvements in
the outpatient management of HF (33). Despite an increas-
ingly complex population of patients, the overall length of
hospital stay has decreased. However, post-discharge event
rates remain disturbingly high, and it is not clear that
hospitalization mitigates these event rates. While we con-
tinue to explore clinical trials evaluating therapies aimed at
reducing subsequent events, simultaneous efforts using
novel management strategies are needed. Emergency phy-
sicians are key stakeholders in this process, because the ED
is the point of triage and disposition for the majority of
patients with HF who are considered for hospital admission.
A focused initial ED evaluation using readily available baseline
data is the first step in identifying patients with HF who may
be eligible for ED discharge. The response to therapy initiated
in the ED constitutes the second level of risk assessment. OU
management may be beneficial for low-risk and intermediate-
risk patients with HF as continued treatment and more precise
risk stratification may ensue, avoiding inpatient admission and
readmission and dispositioning patients to an appropriate level
of care in the hospital. Alternatives to hospitalization, such as
Recommendations forAppropriate Candidates for an OU StayTable 3 Recomm ndatio s forAppropriate Candidates for an OU Stay
High-Risk Features to Avoid in ED Patients Considered for
OU Management
Recommended Suggested
Blood pressure SBP  100 mm Hg SBP  120 mm Hg
Respiratory rate 32 breaths/min NR
Renal function BUN  40 mg/dl NR
Creatinine  3.0 mg/dl NR
ACS No ischemic changes or
elevated troponin
NR
Natriuretic peptides NR BNP  1,000 pg/ml,
NT-proBNP  5,000 pg/ml
ACS  acute coronary syndromes; BNP  B-type natriuretic peptide; BUN  blood urea nitrogen;
ED  emergency department; NR  no recommendations; NT-proBNP  N-terminal pro–B-type
natriuretic peptide; OU  observation unit; SBP  systolic blood pressure.
ardiac
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resources to those high-risk patients in need of intense evalu-
ation and therapy, while facilitating the outpatient manage-
ment of lower-risk patients.
Whether our proposed risk assessment and disposition
strategy is comparable or superior to the current approach
must be compared in a randomized clinical trial. We now
propose such a trial and have summarized the research
algorithm in Figure 1. Patients who are initially evaluated in
the ED and found to be at high risk for inpatient morbidity
Randomized to OU with 
early discharge and 
follow-up 
Intermediate or lo
baseline assessme
stratified accordin
initial response to 
early resolution vs
resolution 
Endpoints:1. Symptoms/s
weight loss; c) QOL. 2. Pr
optimal medical therapy; 
including SCD risk; c) pe
discharge follow-up. 3. O
endpoint); b) 30-day bed d
c) all cause rehospitalizati
Standardized 
outpatient/OU care plan 
deployment; with early 
discharge follow up 
A small subset 
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home from the 
ED 
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HF  heart failure; OU  observation unit; QOL  quality of life; SCD  sudden cand mortality are admitted to an inpatient setting forimmediate intense evaluation and therapy. Those patients
who are initially triaged as at intermediate or low risk and
have some response to initial therapy are randomized to
either OU or inpatient management. Critical end points
include time to symptom resolution and discharge, post-
discharge event rates, and a cost-effective analysis of each
management strategy. With a sample size of 700 patients
(power  0.91, alpha  0.05), the study would be able to
detect a 35% reduction in the odds that the number of bed
days exceeds any chosen cutoff. It is our strong assertion that
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talizations for HF in the near future.
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